Phibro Animal Health (PAHC) Gross Profit Margin starting from the fourth quarter 2026 to fourth quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Phibro Animal Health Corporation  (NASDAQ: PAHC)


Phibro Animal Health's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PAHC Gross Profit Margin (Jun 30 2026)
Q4 		(Mar 31 2026)
Q3 		(Dec 31 2025)
Q2 		(Sep 30 2025)
Q1 		(Jun 30 2025)
Q4
Y / Y Revenue Change 4.4 %
Seq. Revenue Change 3.68 %
Revenue In Millions $396.75
Gross Profit Margin 33.88 %
Gross Profit Margin Total Ranking # 2387
Gross Profit In Millions $134.40
Y / Y Gross Profit Change 22.17 %
Seq. Gross Profit Change 6.94 %


Commenting fourth quarter 2026 Gross Profit Margin
Phibro Animal Health Corporation Gross Profit grew by 6.94 % in Q4 sequentially to 134 millions, while Revenue increased by 3.68 %, this led to improvement in the company's Gross Profit Margin to 33.88 %, above the Phibro Animal Health Corporation average Gross Profit Margin.


Observing fourth quarter 2026 results within Major Pharmaceutical Preparations industry 129 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 2387, from total ranking in the previous quarter at 2477.
Learn about Gross Margin
PAHC's Gross Profit Margin fourth quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 130
Healthcare Sector # 377
Overall # 2368

Gross Profit Margin Statistics
High Average Low
35.5 % 31.71 % 28.95 %
(Dec 31 2025)   (Jun 30 2025)


PAHC Gross Income Trends • More of PAHC's Profitabilty Ratios • PAHC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
PAHC's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
PAHC's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for PAHC's Competitors
Gross Profit Margin Profit Margin for Phibro Animal Health's Suppliers
Gross Profit Margin Profit Margin for PAHC's Customers

You may also want to know
PAHC's Annual Growth Rates PAHC's Profitability Ratios PAHC's Asset Turnover Ratio PAHC's Dividend Growth
PAHC's Roe PAHC's Valuation Ratios PAHC's Financial Strength Ratios PAHC's Gross Profit Growth
PAHC's Roa PAHC's Inventory Turnover Ratio PAHC's Growth Rates PAHC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2026 MRQ Gross ProfitJun 30 2026 MRQ Revenue
Vanda Pharmaceuticals Inc   92.95 %$ 46.969  Millions$ 50.529  Millions
Gyre Therapeutics Inc   92.41 %$ 26.896  Millions$ 29.105  Millions
Aurinia Pharmaceuticals Inc   92.12 %$ 76.665  Millions$ 83.220  Millions
Arcutis Biotherapeutics Inc   91.58 %$ 118.922  Millions$ 129.861  Millions
Urogen Pharma Ltd   90.93 %$ 65.884  Millions$ 72.456  Millions
Acadia Pharmaceuticals Inc   90.81 %$ 279.643  Millions$ 307.959  Millions
Cytokinetics Incorporated  90.46 %$ 25.893  Millions$ 28.624  Millions
Beone Medicines Ltd   89.76 %$ 1,530.541  Millions$ 1,705.071  Millions
Rigel Pharmaceuticals Inc  89.17 %$ 70.178  Millions$ 78.703  Millions
Bioxcel Therapeutics Inc   87.91 %$ 0.160  Millions$ 0.182  Millions
Rhythm Pharmaceuticals Inc   87.47 %$ 62.324  Millions$ 71.255  Millions
United Therapeutics Corporation  87.30 %$ 683.800  Millions$ 783.300  Millions
Ligand Pharmaceuticals Incorporated  87.29 %$ 55.596  Millions$ 63.693  Millions
Jupiter Neurosciences Inc   86.88 %$ 0.021  Millions$ 0.024  Millions
Mannkind Corporation  86.83 %$ 94.965  Millions$ 109.374  Millions
Aclaris Therapeutics Inc   86.62 %$ 1.411  Millions$ 1.629  Millions
Regeneron Pharmaceuticals Inc   86.56 %$ 3,714.200  Millions$ 4,290.700  Millions
Xeris Biopharma Holdings Inc   86.41 %$ 79.588  Millions$ 92.100  Millions
Eli Lilly And Company  85.78 %$ 19,706.000  Millions$ 22,974.000  Millions
Cormedix Inc   85.77 %$ 87.426  Millions$ 101.931  Millions
Indivior Pharmaceuticals Inc   85.71 %$ 294.000  Millions$ 343.000  Millions
Vertex Pharmaceuticals Inc  85.33 %$ 2,844.700  Millions$ 3,333.900  Millions
Ocular Therapeutix Inc   85.08 %$ 11.464  Millions$ 13.475  Millions
Bioadaptives Inc   85.00 %$ 0.004  Millions$ 0.005  Millions
Supernus Pharmaceuticals inc   84.63 %$ 185.389  Millions$ 219.058  Millions
Renovorx Inc   84.27 %$ 0.766  Millions$ 0.909  Millions
Insmed Inc  84.20 %$ 358.274  Millions$ 425.486  Millions
Tg Therapeutics Inc   82.86 %$ 199.141  Millions$ 240.335  Millions
Evofem Biosciences Inc   80.59 %$ 2.122  Millions$ 2.633  Millions
Alkermes Plc   80.22 %$ 397.897  Millions$ 496.009  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.